Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study

Several new, pangenotypic direct-acting antiviral agents (DAAs) have been approved, may reduce the need for genotyping to guide therapy decisions for patients with chronic hepatitis C (CHC). This study aimed to investigate the efficacy and safety of Sofosbuvir (SOF)-based pangenotypic DAAs therapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Wu, Dong-Bo, Jiang, Wei, Chen, Xue-Bin, Xiao, Gui-Bao, Wang, Yong-Hong, Wang, Meng-Lan, Tao, Ya-Chao, Chen, En-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581131/
https://www.ncbi.nlm.nih.gov/pubmed/33120769
http://dx.doi.org/10.1097/MD.0000000000022726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581131/
https://www.ncbi.nlm.nih.gov/pubmed/33120769
http://dx.doi.org/10.1097/MD.0000000000022726

Ejemplares similares